Drug Profile
PolyCAb
Alternative Names: Ovine polyclonal antibodies - MicroPharmLatest Information Update: 28 Jan 2019
Price :
$50
*
At a glance
- Originator MicroPharm
- Class Immunotherapies; Polyclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Clostridium difficile infections
Most Recent Events
- 28 Jan 2019 No recent reports of development identified for phase-I development in Clostridium-difficile-infections in United Kingdom (IV, Injection)
- 31 Mar 2016 MicroPharm completes a phase I trial in Clostridium difficile infections in United Kingdom (ISRCTN80902301)
- 15 Dec 2015 Phase-I clinical trials in Clostridium difficile infections in United Kingdom (IV)